Trial intelligence / Profile preview

PSMA-PET for preoperative planning in melanoma surgery

NCT06560905Phase 2Recruiting

Sponsor
Royal Marsden NHS Foundation Trust
Start
Mar 2025
Primary completion
Dec 2025
Modality
Peptide-Drug Conjugates
Countries
1
01

Overview

A Phase 2 trial of gallium ga-68 gozetotide in Malignant Melanoma (MM), sponsored by Royal Marsden NHS Foundation Trust. Started Mar 2025; status: recruiting.

02

Drugs

gallium ga-68 gozetotide
03

Conditions

Malignant Melanoma (MM)

Beyond the preview

Go deeper on NCT06560905.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06560905.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call